{"filings":[{"id":2088359,"accession_number":"0001520138-26-000312","cik":1580149,"company_name":"BIOVIE INC.","ticker":"BIVI","form_type":"8-K","filed_at":"2026-08-06T11:35:24+00:00","items":["7.01","9.01"],"status":"ready","headline":"BioVie Phase 2 SUNRISE-PD trial of bezisterim shows statistically significant improvements vs placebo","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Statistically significant improvements on MDS-UPDRS Parts I, II, III and composite EPNIC-15 (p=0.0006).","Bezisterim improved biomarkers of neuroinflammation and systemic inflammation; composite neuroinflammation measure p=0.0018.","283 of 380 proteins shifted toward lower inflammatory burden (binomial p=3.2e-22).","Bezisterim well-tolerated; adverse events 39.3% vs 51.7% placebo, no severe/serious AEs.","Conference call scheduled for Aug 12, 2026 to discuss results."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":11161921.555555556,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122035,"accession_number":"0001520138-25-000352","cik":1580149,"company_name":"BIOVIE INC.","ticker":"BIVI","form_type":"8-K","filed_at":"2025-11-13T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Shareholders approve amended 2019 equity plan, increasing authorized shares to 3.1M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment and restatement of 2019 Omnibus Equity Incentive Plan approved at annual meeting on Nov 10, 2025.","Authorized shares increased to 3,100,000 shares from prior limit.","Plan is intended to attract, retain, and incentivize employees, directors, and consultants.","Amended plan effective immediately as of November 10, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":11161921.555555556,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122034,"accession_number":"0001520138-25-000347","cik":1580149,"company_name":"BIOVIE INC.","ticker":"BIVI","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"BioVie shareholders re-elect six directors, ratify auditor, approve equity plan increase","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All 6 nominees elected for one-year terms; Amy Chappell received 1,517,109 for, 36,239 withhold.","Ratification of EisnerAmper LLP as independent auditor for FY2026: 3,245,049 for, 141,868 against.","Amendment to 2019 Omnibus Equity Incentive Plan approved: 1,340,062 for, 207,794 against; broker non-votes 1,864,509.","Equity plan authorized shares increased to 3,100,000, nearly doubling current authorized pool."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.15,"market_cap_usd":11161921.555555556,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138748,"accession_number":"0001520138-25-000249","cik":1580149,"company_name":"BIOVIE INC.","ticker":"BIVI","form_type":"8-K","filed_at":"2025-08-11T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"BioVie raises ~$12M gross in public offering of units (stock + warrants) at $2.00/unit","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$12M from 6M units (5.62M shares + 380K pre-funded) at $2.00/unit.","Net proceeds ~$10.4M after underwriting discounts and estimated expenses.","Each unit includes one share and one warrant exercisable at $2.50 for 5 years.","Warrants (BIVIW) commenced trading on Nasdaq Capital Market on Aug 8, 2025.","Proceeds to be used for working capital and general corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":11161921.555555556,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138747,"accession_number":"0001520138-25-000223","cik":1580149,"company_name":"BIOVIE INC.","ticker":"BIVI","form_type":"8-K","filed_at":"2025-07-23T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"BioVie appoints Amy Chappell and Kameel Farag to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board expanded from 4 to 6 members; appointments effective July 17, 2025.","Dr. Chappell: 25 years at Eli Lilly, led CNS drug development including Cymbalta; former CMO of Eliem Therapeutics.","Mr. Farag: former CFO of Aspen Neuroscience (raised $150M+), SVP Finance at Ionis, Regional CFO at Amgen.","BioVie advancing bezisterim Phase 2 trials for early Parkinson's (SUNRISE-PD) and long COVID (ADDRESS-LC)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":11161921.555555556,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156196,"accession_number":"0001520138-25-000190","cik":1580149,"company_name":"BIOVIE INC.","ticker":"BIVI","form_type":"8-K","filed_at":"2025-06-27T23:59:59+00:00","items":["3.03"],"status":"ready","headline":"BioVie board effectuates 1-for-10 reverse stock split effective July 7, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split ratio of 1-for-10 becomes effective at 12:01 am ET on July 7, 2025.","Board approved the split on June 26, 2025; stockholders had authorized the action on June 23, 2025.","No fractional shares issued; shareholders entitled to a fractional share receive one full post-split share.","New CUSIP number 09074F504; trading on Nasdaq continues on split-adjusted basis.","Outstanding options, restricted stock units, and warrants adjusted proportionally with exercise prices increased."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":11161921.555555556,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156195,"accession_number":"0001520138-25-000185","cik":1580149,"company_name":"BIOVIE INC.","ticker":"BIVI","form_type":"8-K","filed_at":"2025-06-24T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"BioVie shareholders authorize reverse stock split at ratio of 1:5 to 1:10","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["8,664,435 voted for the reverse stock split authority, 2,200,874 against, 105,722 abstain.","Board has discretion to implement the split at any ratio between 1-for-5 and 1-for-10 within one year.","Proposal to adjourn the special meeting if needed also passed: 8,788,143 for, 2,033,834 against.","Total 10,971,031 shares present at the meeting out of 18,570,726 outstanding (quorum achieved)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":11161921.555555556,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174644,"accession_number":"0001520138-25-000089","cik":1580149,"company_name":"BIOVIE INC.","ticker":"BIVI","form_type":"8-K","filed_at":"2025-03-28T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"BioVie board member Dr. Robert Hariri resigns effective March 28, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Robert Hariri resigned from BioVie's Board of Directors on March 28, 2025.","Resignation not due to any disagreement with the company's operations, policies, or practices.","Hariri had served on the board since June 2020 and on the Nominating and Corporate Governance Committee."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":11161921.555555556,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191614,"accession_number":"0001520138-24-000410","cik":1580149,"company_name":"BIOVIE INC.","ticker":"BIVI","form_type":"8-K","filed_at":"2024-11-08T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"BioVie shareholders approve equity plan increase to 1.25M shares; all directors elected","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All six director nominees (Lang, Do, Sherman, Berman, Hariri, Rogich) elected with majorities.","Ratification of EisnerAmper LLP as independent auditor for fiscal 2025 approved (4,526,100 for).","Non-binding say-on-pay proposal on executive compensation approved (3,004,131 for).","Amendment to 2019 Omnibus Equity Incentive Plan increasing authorized shares to 1,250,000 approved (2,963,641 for)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":11161921.555555556,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191613,"accession_number":"0001520138-24-000404","cik":1580149,"company_name":"BIOVIE INC.","ticker":"BIVI","form_type":"8-K","filed_at":"2024-10-29T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"BioVie closes registered direct offering raising $3.24M gross proceeds at $2.83/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Closed registered direct offering of 1,146,000 shares at $2.83/share, gross proceeds ~$3.24M.","Net proceeds after fees of ~$419K are approx. $2.82M; funds for working capital and corporate purposes.","ThinkEquity acted as sole placement agent; offering made under shelf registration S-3.","BioVie is a clinical-stage company developing therapies for liver disease and neurological disorders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":11161921.555555556,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191612,"accession_number":"0001520138-24-000400","cik":1580149,"company_name":"BIOVIE INC.","ticker":"BIVI","form_type":"8-K","filed_at":"2024-10-29T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"BioVie prices $3.2M registered direct offering of 1.146M shares at $2.83/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 1,146,000 shares at $2.83 per share, gross proceeds ~$3.2M.","Net proceeds to be used for working capital and general corporate purposes.","Placement agent warrant for 57,300 shares at $3.5375 (125% of offering price).","Offering expected to close on October 29, 2024, subject to customary conditions.","ThinkEquity acting as sole placement agent; securities sold under effective shelf registration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":11161921.555555556,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191611,"accession_number":"0001520138-24-000387","cik":1580149,"company_name":"BIOVIE INC.","ticker":"BIVI","form_type":"8-K","filed_at":"2024-10-24T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"BioVie closes $6M registered direct offering of 2.67M shares at $2.25/share with warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Closed offering of 2,667,000 shares at $2.25 per share for gross proceeds of $6,000,750.","Concurrent private placement of warrants to purchase up to 2,667,000 shares at $2.12/exercise price.","Net proceeds ~$5.33M after fees; intended for working capital and general corporate purposes.","Warrants exercisable beginning 6 months after issuance, expiring 5 years after initial exercise date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":11161921.555555556,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191610,"accession_number":"0001520138-24-000379","cik":1580149,"company_name":"BIOVIE INC.","ticker":"BIVI","form_type":"8-K","filed_at":"2024-10-24T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"BioVie prices $6.0M registered direct offering at $2.25/share; issues warrants at $2.12","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of ~$6,000,750 from 2,667,000 shares of common stock at $2.25 per share.","Concurrent private placement of warrants to purchase 2,667,000 shares at $2.12/share, exercisable after 6 months, expiring 5 years later.","Closing expected on October 24, 2024; ThinkEquity acting as sole placement agent.","Net proceeds to be used for working capital and general corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":11161921.555555556,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191609,"accession_number":"0001520138-24-000376","cik":1580149,"company_name":"BIOVIE INC.","ticker":"BIVI","form_type":"8-K","filed_at":"2024-10-22T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"BioVie closes registered direct offering of 4.44M shares at $1.50, raising $6.66M gross","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Closed registered direct offering of 4,443,000 shares at $1.50/share for gross proceeds of $6,664,500.","Concurrent private placement of warrants to buy up to 4,443,000 shares at $1.37/share, exercisable after six months for five years.","Net proceeds after ~$902,560 in fees will fund working capital and general corporate purposes.","Acuitas warrant exercise price adjusted from $1.53 to $1.37 due to anti-dilution provision triggered by the offering."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":11161921.555555556,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191608,"accession_number":"0001520138-24-000372","cik":1580149,"company_name":"BIOVIE INC.","ticker":"BIVI","form_type":"8-K","filed_at":"2024-10-22T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"BioVie prices $6.66M registered direct offering of 4.44M shares at $1.50/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of ~$6.66M from sale of 4,443,000 shares at $1.50/share in registered direct offering.","Concurrent private placement of warrants to purchase 4,443,000 shares at $1.37/exercise price, exercisable in 6 months for 5 years.","Placement agent ThinkEquity receives warrant for 222,150 shares at $1.875/share.","Net proceeds to be used for working capital and general corporate purposes.","Offering expected to close on October 22, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":11161921.555555556,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208083,"accession_number":"0001520138-24-000320","cik":1580149,"company_name":"BIOVIE INC.","ticker":"BIVI","form_type":"8-K","filed_at":"2024-09-25T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"BioVie closes $3M public offering of shares and warrants at $1.53/unit","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Closed best efforts offering of 1,360,800 shares, pre-funded warrants for 600,000 shares, and 1,960,800 common warrants.","Gross proceeds of ~$3.0M; net proceeds ~$2.79M after placement agent fees and expenses.","Acuitas warrant exercise price adjusted from $10.00 to $1.53 per share due to anti-dilution provision.","Net proceeds to be used primarily for working capital and general corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":11161921.555555556,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208082,"accession_number":"0001520138-24-000310","cik":1580149,"company_name":"BIOVIE INC.","ticker":"BIVI","form_type":"8-K","filed_at":"2024-09-24T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"BioVie prices $3M public offering of 1.96M units at $1.53/share with warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$3M from 1,960,800 units at $1.53 each; each unit includes share or pre-funded warrant plus 5-year warrant exercisable at $1.53.","Offering expected to close September 25, 2024; ThinkEquity acting as sole placement agent.","Net proceeds to be used for working capital and general corporate purposes.","BioVie is a clinical-stage company focused on liver disease and neurodegenerative disorders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":11161921.555555556,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208078,"accession_number":"0001520138-24-000313","cik":1580149,"company_name":"BIOVIE INC.","ticker":"BIVI","form_type":"8-K/A","filed_at":"2024-09-24T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"BioVie files 8-K/A solely to replace legal opinion exhibit for Sept 2024 offering","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Amendment corrects Exhibit 5.1; no changes to offering terms or other disclosures.","Original offering: up to 1,960,800 shares at $1.53/share plus warrants and pre-funded warrants.","No new financial, operational, or business information provided in this amendment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":11161921.555555556,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208081,"accession_number":"0001520138-24-000282","cik":1580149,"company_name":"BIOVIE INC.","ticker":"BIVI","form_type":"8-K","filed_at":"2024-08-21T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"BioVie regains Nasdaq minimum bid price compliance after 10-day $1 closing streak","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq compliance letter on August 20, 2024 for Bid Price Rule (5550(a)(2)).","Bid price closed at or above $1.00 for 10 consecutive business days (Aug 6–19, 2024).","Previously disclosed bid price deficiency in April 2024; now resolved.","Company states it will continue to work to adhere to Nasdaq listing standards."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":11161921.555555556,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208077,"accession_number":"0001520138-24-000263","cik":1580149,"company_name":"BIOVIE INC.","ticker":"BIVI","form_type":"8-K/A","filed_at":"2024-08-06T23:59:59+00:00","items":["9.01","3.03","5.03"],"status":"ready","headline":"BioVie files corrective certificates for 1:10 reverse stock split; terms unchanged","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Filed Certificate of Amendment on Aug 2, 2024 to correct a defect in the original Certificate of Change.","Filed Certificate of Termination on Aug 5, 2024 voiding the defective Certificate of Change.","No change to the 1:10 reverse stock split ratio or timing from the original disclosure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":11161921.555555556,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208080,"accession_number":"0001520138-24-000254","cik":1580149,"company_name":"BIOVIE INC.","ticker":"BIVI","form_type":"8-K","filed_at":"2024-08-01T23:59:59+00:00","items":["3.03","5.03","5.07","9.01"],"status":"ready","headline":"BioVie shareholders approve 1-for-10 reverse stock split effective Aug 6, 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved reverse split ratio of 1-for-10; Board exercised authority on July 29, 2024.","Reverse split effective at 12:01 am ET on August 6, 2024; CUSIP changes to 09074F405.","Vote: 39,393,584 for, 3,204,131 against, 204,190 abstain; no broker non-votes.","No change in authorized shares; fractional shares rounded up to one full share.","Outstanding options, RSUs, and warrants adjusted proportionately; exercise prices increased."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":11161921.555555556,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208079,"accession_number":"0001520138-24-000251","cik":1580149,"company_name":"BIOVIE INC.","ticker":"BIVI","form_type":"8-K","filed_at":"2024-07-30T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Steve Gorlin resigns from BioVie board effective July 25, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Steve Gorlin resigned as director of BioVie on July 25, 2024, effective immediately.","Resignation was not due to any dispute or disagreement with the company or board.","Company thanked Mr. Gorlin for his service and contributions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":11161921.555555556,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225622,"accession_number":"0001520138-24-000179","cik":1580149,"company_name":"BIOVIE INC.","ticker":"BIVI","form_type":"8-K","filed_at":"2024-04-19T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"BioVie receives Nasdaq delisting notice; has 180 days to regain compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified BioVie that its stock closed below $1.00 for 30 consecutive business days.","Company granted 180-day grace period until October 15, 2024 to meet minimum bid price.","Compliance requires closing bid price of at least $1.00 for 10 consecutive business days.","Eligible for second 180-day extension if other Nasdaq initial listing standards are met.","Currently has stockholders' equity of at least $5 million; no assurance of regaining compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":11161921.555555556,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244792,"accession_number":"0001520138-24-000105","cik":1580149,"company_name":"BIOVIE INC.","ticker":"BIVI","form_type":"8-K","filed_at":"2024-03-11T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"BioVie updates pipeline; plans Phase 2b PD trial summer 2024, delays AD Phase 3 to 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Raised $18.8M net ($21M gross) in equity financing to fund near-term priorities.","Phase 2b monotherapy trial of NE3107 in Parkinson's planned for late summer 2024; 100–150 patients.","Phase 3 Alzheimer's trial postponed to early 2025 to use once-daily NE3107 formulation.","BIV201 Phase 3 in ascites delayed pending partnership; FDA guidance received.","Previous NE3107 data showed 68% slowing on CDR-SB in AD and improved non-motor symptoms in PD."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":11161921.555555556,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244791,"accession_number":"0001520138-24-000098","cik":1580149,"company_name":"BIOVIE INC.","ticker":"BIVI","form_type":"8-K","filed_at":"2024-03-06T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"BioVie closes ~$21M public offering of stock and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 15M shares, pre-funded warrants for 6M shares, and common warrants for 10.5M shares at $1.00 combined price.","Gross proceeds ~$21M; net after placement agent fees and expenses of ~$2.2M.","Common warrants exercisable at $1.50 per share for five years from issuance.","Acuitas warrant exercise price adjusted from $1.82 to $1.00 per the offering price.","Company intends net proceeds for working capital and general corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":11161921.555555556,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244790,"accession_number":"0001520138-24-000086","cik":1580149,"company_name":"BIOVIE INC.","ticker":"BIVI","form_type":"8-K","filed_at":"2024-03-04T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"BioVie announces $21M public offering of 21M shares at $1.00 with warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 21,000,000 common shares (or pre-funded warrants) at $1.00 per share, plus warrants to purchase up to 10,500,000 shares at $1.50.","Gross proceeds ~$21 million; net proceeds for working capital and general corporate purposes.","ThinkEquity is sole placement agent; offering expected to close March 6, 2024.","Pre-funded warrants exercisable at $0.0001 per share; common warrants exercisable at $1.50 for 5 years."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":11161921.555555556,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244786,"accession_number":"0001520138-24-000092","cik":1580149,"company_name":"BIOVIE INC.","ticker":"BIVI","form_type":"8-K/A","filed_at":"2024-03-04T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"BioVie raises up to $21M in equity offering with warrants; files amendment to 8-K","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of up to 21 million shares of common stock at $1.00 per share.","Pre-funded warrants offered at $0.9999 per warrant; each exercisable for one share.","Class A common stock purchase warrants to purchase up to 10.5 million shares.","Placement agent is ThinkEquity LLC.","Amendment filed to include legal opinions from Sherman & Howard and Reed Smith."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":11161921.555555556,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244789,"accession_number":"0001520138-24-000079","cik":1580149,"company_name":"BIOVIE INC.","ticker":"BIVI","form_type":"8-K","filed_at":"2024-03-01T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"BioVie's NE3107 shows PD Phase 2a non-motor symptom improvement; AD Phase 3 misses significance but biomarker gains","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["PD Phase 2a: NE3107 improved sleep/fatigue NMSS domain -2.4 pts vs placebo +1.0 (p=0.0159); correlated with motor improvements.","PD: 26% of NE3107 patients had better morning motor scores vs 0% placebo (p=0.046); younger patients saw >6 point UPDRS advantage.","AD Phase 3 missed significance per protocol; NE3107 showed 68% slowing of decline on CDR-SB and 26% on ADAS-COG-12.","AD biomarkers: NE3107 associated with biological age deceleration -3.87 years (p=0.012), reduced fasting glucose and cholesterol.","Principal component analysis suggests NE3107 may realign metabolic inflammation; data presented at AD/PD 2024 in Lisbon."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":11161921.555555556,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244788,"accession_number":"0001520138-24-000045","cik":1580149,"company_name":"BIOVIE INC.","ticker":"BIVI","form_type":"8-K","filed_at":"2024-01-25T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"BioVie hit with shareholder class action over NE3107 trial disclosures","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Lawsuit filed Jan 19, 2024 in Nevada federal court (Olmstead v. BioVie Inc., No. 3:24-cv-00035).","Alleges material misrepresentations/omissions about NE3107 study and trial under Sections 10(b) and 20(a).","Class period: Aug 5, 2021 through Nov 29, 2023; seeks unspecified monetary damages and fees.","Company believes lawsuit is without merit and intends to defend vigorously."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":11161921.555555556,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244787,"accession_number":"0001520138-24-000034","cik":1580149,"company_name":"BIOVIE INC.","ticker":"BIVI","form_type":"8-K","filed_at":"2024-01-19T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"BioVie files prospectus supplement for up to $25M ATM; already raised $59.4M from 8.1M shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Filed prospectus supplement under new shelf registration (333-274083) for continued at-the-market sales of common stock.","As of Jan 19, 2024, issued 8,136,058 shares under existing Sales Agreement with Cantor Fitzgerald for net proceeds of $59.4M.","Commissions and expenses totaled ~$1.8M; new shelf effective Aug 28, 2023 replaces expiring Feb 2, 2024 shelf.","Up to $25M aggregate offering price authorized under the new supplement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":11161921.555555556,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":262230,"accession_number":"0001520138-23-000511","cik":1580149,"company_name":"BIOVIE INC.","ticker":"BIVI","form_type":"8-K","filed_at":"2023-11-29T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"BioVie Phase 3 NE3107 Alzheimer's trial misses primary endpoint; positive per-protocol trends","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Primary endpoint missed statistical significance due to exclusion of patients from 15 sites with GCP violations; sites referred to FDA.","Per-protocol analysis (57 patients) showed NE3107 cognitive and functional improvement vs placebo comparable to approved monoclonal antibodies.","NE3107-treated patients had 4.66-year age deceleration advantage vs placebo via Horvath DNA methylation clock.","Company plans to work with FDA on adaptive design to continue enrolling patients toward statistical significance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":11161921.555555556,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":262229,"accession_number":"0001520138-23-000488","cik":1580149,"company_name":"BIOVIE INC.","ticker":"BIVI","form_type":"8-K","filed_at":"2023-11-13T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"BioVie shareholders elect directors and ratify EisnerAmper as auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Shareholders elected all 7 director nominees: Cuong Do, Jim Lang, Michael Sherman, Richard J. Berman, Steve Gorlin, Robert Hariri, Sigmund Rogich.","For each director, votes for ranged from 24.5M to 24.9M; broker non-votes were 4.53M.","Ratification of EisnerAmper LLP as independent auditor for fiscal 2024: 29.28M for, 19k against, 155 abstain.","Annual meeting held November 8, 2023; results filed November 13, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":11161921.555555556,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":262228,"accession_number":"0001520138-23-000457","cik":1580149,"company_name":"BIOVIE INC.","ticker":"BIVI","form_type":"8-K","filed_at":"2023-10-25T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"BioVie presents blinded Phase 3 NE3107 data at CTAD; cognitive, biomarker improvements observed","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Blinded data (n=322) show statistically significant population changes from baseline on ADAS-Cog12, ADCS-CGIC, MMSE, CDR, CDR-SB, ADCOMS, ADL.","Apparent reduction in amyloid burden: 36.5% of PrecivityAD-positive patients reverted to negative after 30 weeks.","Significant increases in insulin and beta cell function (HOMA2-%B +13.5%, p<0.0001) without hypoglycemia.","FDG-PET SUVRs increased in 10 of 21 sub-study patients, suggesting reduced amyloid burden.","Company expects unblinded topline data in late November or early December 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":11161921.555555556,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":279429,"accession_number":"0001520138-23-000375","cik":1580149,"company_name":"BIOVIE INC.","ticker":"BIVI","form_type":"8-K","filed_at":"2023-09-11T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"BioVie updates investor presentation on September 8, 2023","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Filed updated investor presentation (Exhibit 99.1) as of September 8, 2023.","Presentation available under 'Events and Presentations' on company website.","No material financial or operational updates disclosed in filing text."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":11161921.555555556,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":297818,"accession_number":"0001520138-23-000181","cik":1580149,"company_name":"BIOVIE INC.","ticker":"BIVI","form_type":"8-K","filed_at":"2023-04-07T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"BioVie terminates B. Riley as ATM agent; updates prior equity sales of $48.8M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Mutually terminated B. Riley as sales agent under Controlled Equity Offering Sales Agreement; Cantor Fitzgerald remains agent.","As of Apr 3, 2023, issued 7,391,228 shares for net proceeds of $48.8M after ~$1.7M commissions and expenses.","Filed prospectus supplement to offer up to $17.5M in aggregate offering price of Class A common stock under the agreement.","Shares sold under Company's effective S-3 registration statement (333-252386) declared effective Feb 2, 2021."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":11161921.555555556,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":318072,"accession_number":"0001520138-23-000148","cik":1580149,"company_name":"BIOVIE INC.","ticker":"BIVI","form_type":"8-K","filed_at":"2023-03-23T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"BioVie updates investor presentation on March 23, 2023; no specific details disclosed in filing","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["BioVie (BIVI) furnished an updated investor presentation as Exhibit 99.1 under Item 7.01.","Presentation is available on the company's website under the investors section.","No financial or clinical data from the presentation are included in this 8-K; details are limited.","Company provides no admission of materiality from the presentation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":11161921.555555556,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":318071,"accession_number":"0001520138-23-000131","cik":1580149,"company_name":"BIOVIE INC.","ticker":"BIVI","form_type":"8-K","filed_at":"2023-03-13T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"BioVie board approves bylaw amendment on special meetings and director count","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Chairman and CEO now authorized to call special board meetings with at least four hours' notice.","Required director count reduced from exactly nine to a range of three to eleven.","Amendment effective immediately as of March 12, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":11161921.555555556,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":318070,"accession_number":"0001520138-23-000124","cik":1580149,"company_name":"BIOVIE INC.","ticker":"BIVI","form_type":"8-K","filed_at":"2023-03-06T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"BioVie Chairman Terren Peizer resigns after being charged with insider trading of Ontrak Inc.","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Resignation effective March 2, 2023; Peizer charged by DOJ and SEC for alleged insider trading of Ontrak Inc.","Peizer's resignation is not due to any disagreement with BioVie's operations, policies, or practices.","Board elected current director Jim Lang as new Chairman, effective immediately.","Peizer had served as Chairman; his departure follows separate legal actions unrelated to BioVie."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":11161921.555555556,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":336350,"accession_number":"0001520138-22-000583","cik":1580149,"company_name":"BIOVIE INC.","ticker":"BIVI","form_type":"8-K","filed_at":"2022-12-23T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"BioVie files prospectus supplement for $17.5M ATM offering; already raised $29M","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Filed prospectus supplement on Dec 23, 2022 for up to $17.5M in Class A common stock sales.","As of Dec 20, 2022, issued 3,709,509 shares under existing ATM for net proceeds of $29.0M.","Sales agents are Cantor Fitzgerald & Co. and B. Riley Securities, Inc.","New shares offered under Registration Statement No. 333-252386 via the August 31, 2022 Sales Agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":11161921.555555556,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":336349,"accession_number":"0001520138-22-000566","cik":1580149,"company_name":"BIOVIE INC.","ticker":"BIVI","form_type":"8-K","filed_at":"2022-12-15T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"BioVie files prospectus supplement for up to $17.5M ATM offering","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["At-the-market offering of up to $17.5M of Class A common stock via Cantor Fitzgerald & Co. and B. Riley Securities.","Shares sold under existing S-3 registration statement; proceeds for general corporate purposes.","Legal opinion on share validity filed as Exhibit 5.1; offering subject to market conditions.","No immediate sale; company may sell shares from time to time at prevailing market prices."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":11161921.555555556,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":336348,"accession_number":"0001520138-22-000553","cik":1580149,"company_name":"BIOVIE INC.","ticker":"BIVI","form_type":"8-K","filed_at":"2022-12-07T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"BioVie reports positive NE3107 data in Parkinson's, Alzheimer's, and aging biomarkers","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["NE3107+levodopa improved UPDRS Part 3 by 3+ points vs levodopa alone at 2-3 hours (clinically meaningful); 6+ points for patients <70.","NE3107 improved cognition: ADAS-Cog12 +2.2 points (p=0.0173), CDR +0.11 (p=0.0416), ADCOMS +0.07 (p=0.0094) in mild cognitive impairment/mild AD.","NE3107 reduced Horvath DNA methylation SkinBlood clock by 3.3 years (p=0.0021) after 3 months; 19 of 22 patients showed reduction.","BioVie increased Phase 3 AD trial enrollment from 316 to 400; topline results expected before end of Q3 2023.","Company plans to discuss Phase 3 Parkinson's program with FDA and expects to launch Phase 3 trials in 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":11161921.555555556,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":336347,"accession_number":"0001520138-22-000548","cik":1580149,"company_name":"BIOVIE INC.","ticker":"BIVI","form_type":"8-K","filed_at":"2022-12-06T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"BioVie announces positive Phase 2 results for NE3107 in Parkinson's and Alzheimer's; epigenetic age reduced 3.3 years","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["PD trial: NE3107+levodopa improved UPDRS Part 3 by 3+ points vs levodopa alone; under-70 patients saw 6-point superiority.","AD trial: 2.1-point improvement on ADAS-Cog12 (p=0.0173) in MCI/mild AD patients; CSF p-tau reduced by 1.66 pg/mL.","18 of 22 AD patients showed improvement on functional MRI; no drug-related adverse events reported.","DNA methylation analysis: Horvath SkinBlood clock reduced by 3.3 years (p=0.0021) after 3 months; 19 of 22 patients showed reduction.","Full Parkinson's data to be presented at AD/PD 2023 conference in March-April 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":11161921.555555556,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":336346,"accession_number":"0001520138-22-000546","cik":1580149,"company_name":"BIOVIE INC.","ticker":"BIVI","form_type":"8-K","filed_at":"2022-12-06T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"BioVie increases ATM offering capacity from $8.1M to $17.5M under sales agreement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Filed prospectus supplement on Dec. 6, 2022 to raise maximum aggregate offering from $8.1M to $17.5M.","Previously issued and sold 1,934,871 shares for net proceeds of approximately $7.4M (after ~$228K in fees).","Shares sold via Controlled Equity Offering through agents Cantor Fitzgerald & Co. and B. Riley Securities.","Up to $17.5M in additional shares of Class A common stock may now be sold under the at-the-market program.","Prospectus supplement filed due to increase in public float since prior supplement dated Sept. 30, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":11161921.555555556,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":336345,"accession_number":"0001520138-22-000509","cik":1580149,"company_name":"BIOVIE INC.","ticker":"BIVI","form_type":"8-K","filed_at":"2022-11-10T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"BioVie shareholders elect all 8 director nominees and ratify auditors at 2022 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All eight director nominees (Terren Peizer, Cuong Do, Jim Lang, Michael Sherman, Richard Berman, Steve Gorlin, Robert Hariri, Sigmund Rogich) elected with high approval (23.78M–23.92M for).","Ratification of EisnerAmper LLP as independent auditor for FY 2023 approved: 25.62M for, 0.09M against, 0.01M abstain.","Broker non-votes of 1.76M shares recorded on director elections; no broker non-votes on auditor ratification as it is a routine matter."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.0,"calibrated_materiality_score":0.0,"market_cap_usd":11161921.555555556,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":336344,"accession_number":"0001520138-22-000448","cik":1580149,"company_name":"BIOVIE INC.","ticker":"BIVI","form_type":"8-K","filed_at":"2022-10-05T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"BioVie reports 82% responder rate in Phase 2 Alzheimer's study; Phase 3 on track for mid-2023 readout","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["82% of MCI/mild AD patients improved cognition (modified ADAS-Cog12) after 3 months; mean improvement -2.6 points (p=0.0046).","Phase 3 NE3107 Alzheimer's trial has enrolled >50% of 316 patients; topline data expected mid-2023.","Phase 2 Parkinson's NE3107 trial expected to read out by end of 2022; early blinded data consistent with animal studies.","Phase 2b BIV201 ascites trial enrollment slowed by COVID; topline data now expected mid-2023.","Full data from exploratory Alzheimer's study to be presented at CTAD conference Nov 29–Dec 2, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":11161921.555555556,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":353747,"accession_number":"0001520138-22-000390","cik":1580149,"company_name":"BIOVIE INC.","ticker":"BIVI","form_type":"8-K","filed_at":"2022-09-07T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"BioVie NE3107 Phase 2 trial: 82% of mild AD patients improved ADAS-Cog12 by 2.6 pts (p=0.0046); Phase 3 50% enrolled","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["23-patient open-label Phase 2: 82% of mild AD patients (MMSE>=20) showed mean 2.6-point ADAS-Cog12 improvement (p=0.0046); no drug-related adverse events.","Reduction in TNF alpha significantly correlated with cognitive improvement (R=0.70, p=0.0077).","Phase 3 AD trial (NCT04669028) 50% enrolled of 316 target; DSMB review later in 2022 may adjust sample size up to 400; topline expected mid-2023.","Phase 2 Parkinson's trial (NCT05083260) enrolling 40 patients; data readout by end of 2022; no drug-related AEs seen yet.","Phase 2b BIV201 trial in refractory ascites enrollment delayed by COVID; data readout now anticipated by mid-2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":11161921.555555556,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":353744,"accession_number":"0001520138-22-000392","cik":1580149,"company_name":"BIOVIE INC.","ticker":"BIVI","form_type":"8-K/A","filed_at":"2022-09-07T23:59:59+00:00","items":["9.01","7.01","8.01"],"status":"ready","headline":"BioVie announces Phase 2 Alzheimer's results for NE3107 with cognitive and biomarker improvements","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["82% of 17 mild AD patients showed 2.6-point decrease in ADAS-Cog12 (p=0.046) after 3 months of NE3107.","NE3107 significantly reduced TNF-alpha; improvements in cognition correlated with TNF reduction (R=0.70, p=0.0077).","Phase 3 AD trial (NCT04669028) half enrolled; topline data expected mid-2023, subject to DSMB review.","Phase 2 Parkinson's trial (NCT05083260) enrolling; data readout by end of 2022; early efficacy signal detected.","Phase 2b BIV201 trial for ascites delayed by COVID; data readout anticipated mid-2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":11161921.555555556,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":353746,"accession_number":"0001520138-22-000388","cik":1580149,"company_name":"BIOVIE INC.","ticker":"BIVI","form_type":"8-K","filed_at":"2022-08-31T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"BioVie enters $20M at-the-market equity sales agreement with Cantor and B. Riley","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Up to $20M of Class A common stock may be sold through agents Cantor Fitzgerald and B. Riley in at-the-market offerings.","Agents receive 3% commission on gross proceeds; company reimburses up to $75k in expenses.","Proceeds intended for general corporate purposes and working capital.","Company has no obligation to sell shares; may suspend or terminate at any time."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":11161921.555555556,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":353743,"accession_number":"0001520138-22-000313","cik":1580149,"company_name":"BIOVIE INC.","ticker":"BIVI","form_type":"8-K/A","filed_at":"2022-07-18T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"BioVie enters $6M private placement with controlling stockholder Acuitas Group; issues shares and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 3,636,364 shares at $1.65/share to Acuitas Group Holdings, LLC, a related party controlled by chairman Terren Peizer.","Warrant to purchase 7,272,728 shares at $1.82 exercise price, five-year term.","Aggregate purchase price approximately $6 million; expected closing on or about August 15, 2022.","Proceeds to be used for working capital; registration rights to be amended to cover resale of shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":11161921.555555556,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":353745,"accession_number":"0001520138-22-000305","cik":1580149,"company_name":"BIOVIE INC.","ticker":"BIVI","form_type":"8-K","filed_at":"2022-07-15T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"BioVie raises $6M in private placement with controlling stockholder Acuitas Group","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sale of 3,636,364 shares at $1.65 plus warrant for 7,272,728 shares at $1.82 for aggregate $6M.","Closing expected August 15, 2022; net proceeds used for working capital.","Oppenheimer & Co. acted as sole placement agent with 3% cash fee.","Acuitas is 100% owned by chairman Terren Peizer; related-party transaction.","Existing Registration Rights Agreement to be amended to cover PIPE shares and warrant shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":11161921.555555556,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-07-15T23:59:59+00:00|353745"}